GlassScriptPhysician profile
Sachin Gupta
NPI 1144343005
$117,484.49
in general payments reported to CMS, 2019-2025
51 companies · $7,457 in 2025
The $7,457 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $11K · 2021: $18K · 2022: $9,615 · 2023: $18K · 2024: $14K · 2025: $7,457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,150 · Honoraria: $4,550 · Food and Beverage: $3,604 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,725 · Travel and Lodging: $1,467 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,555.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,150.00 |
| Honoraria | $4,550.00 |
| Food and Beverage | $3,603.78 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,725.00 |
| Travel and Lodging | $1,467.39 |
| Education | $114.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $38,438.12 | 2019-2024 | Neulasta, Mvasi, Kyprolis |
| Incyte Corporation | $24,402.93 | 2021-2024 | Monjuvi |
| Genzyme Corporation | $18,730.49 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $5,769.65 | 2021-2025 | Imfinzi |
| Abbvie INC. | $4,687.62 | 2020-2025 | |
| Novocure INC. | $4,639.90 | 2023 | |
| Seagen INC. | $3,489.73 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $3,466.08 | 2019-2024 | Opdualag, Opdivo |
| Astellas Pharma US INC | $2,679.14 | 2023-2025 | Padcev, Vyloy |
| Beigene USA, INC. | $2,303.53 | 2021-2024 | Brukinsa |
| Cti Biopharma Corp. | $1,725.00 | 2023 | Vonjo |
| Pharmacosmos Therapeutics INC. | $1,697.97 | 2021-2025 | Monoferric |
| Aveo Pharmaceuticals, INC. | $1,210.00 | 2024 | |
| Celgene Corporation | $745.90 | 2019-2025 | Opdualag, Pomalyst, Reblozyl |
| Daiichi Sankyo INC. | $344.57 | 2021-2024 | Injectafer, Enhertu |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sachin Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.